Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-173672
Filing Date
2026-04-23
Accepted
2026-04-23 16:06:01
Documents
19
Period of Report
2026-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A d64525ddef14a.htm   iXBRL DEF 14A 1146312
3 GRAPHIC g64525g00a01.jpg GRAPHIC 49962
4 GRAPHIC g64525g01g43.jpg GRAPHIC 98494
5 GRAPHIC g64525g01g44.jpg GRAPHIC 65733
6 GRAPHIC g64525g01g69.jpg GRAPHIC 130809
7 GRAPHIC g64525g01g70.jpg GRAPHIC 130553
8 GRAPHIC g64525snap14.jpg GRAPHIC 4920
9 GRAPHIC g64525snap15.jpg GRAPHIC 9048
  Complete submission text file 0001193125-26-173672.txt   3067671

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pcvx-20251231.xsd EX-101.SCH 6442
22 EXTRACTED XBRL INSTANCE DOCUMENT d64525ddef14a_htm.xml XML 258575
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39323 | Film No.: 26888634
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)